Faruqi & Faruqi Urges Aardvark Investors to Act Before 2026 Deadline

Legal Alert for Aardvark Investors

Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, has issued a critical reminder for investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD). The firm encourages affected investors to consider stepping forward as lead plaintiffs in an ongoing federal securities class action lawsuit before the looming deadline on October 13, 2026.

Overview of the Class Action

The lawsuit arises from allegations that Aardvark and its executives violated federal securities laws by making misleading statements regarding the safety and efficacy of their product, ARD-101. According to court filings, potential investors were not adequately informed about the risks associated with this drug, leading to overestimated clinical and commercial prospects.

This lawsuit includes all individuals or entities that acquired Aardvark common stock linked to the Offering Documents from the company's initial public offering around February 13, 2025, or those who purchased the company's securities between February 13, 2025, and May 14, 2026. Investors who suffered losses during this timeframe are eligible to take part in the class action, which is already underway.

Call to Action for Investors

Faruqi & Faruqi's Senior Partner, James (Josh) Wilson, is primarily handling inquiries related to this case. The firm invites investors who believe they may qualify to reach out directly for discussions regarding their rights and to comprehend their options better. Interested parties can find additional resources via the law firm’s website or by calling Josh Wilson directly at 877-247-4292.

Investors choosing to participate as lead plaintiffs will play a pivotal role in guiding the litigation process, advocating for the collective interests of Aardvark shareholders. It is essential that they act promptly, as the court restricts applications for lead plaintiff status to those who can substantiate their financial stake in any potential recovery.

Key Allegations in the Case

The complaint leverages multiple allegations against Aardvark, highlighting three primary failure points:
1. Underreported Safety Risks: Aardvark represented ARD-101 as safer than what clinical evidence supports, misleading investors about the drug's true risk profile.
2. Inflated Success Projections: The company overstated the prospects of ARD-101 regarding regulatory approvals and market potential, creating an unrealistic view of the company’s future.
3. Misleading Public Statements: Throughout the relevant periods, Aardvark’s public communications were allegedly rife with inaccuracies that could have influenced investors' decision-making processes.

Following disclosures that revealed these discrepancies, Aardvark shares reportedly plummeted by approximately 32% on May 15, 2026, further fueling the case against the company.

Importance of Seeking Legal Counsel

Potential participants in this lawsuit may include whistleblowers, former employees, and other parties with relevant information about Aardvark’s practices. Faruqi & Faruqi are dedicated to corporate accountability and empowerment for their clients. Investors are encouraged not to hesitate in reaching out for clarification on their legal rights and potential claims related to their investments.

Investors must recognize that their ability to receive any recovery is independent of their decision to serve as a lead plaintiff or remain an absent class member. Their rights will still be preserved regardless of their engagement with this litigation. Faruqi & Faruqi emphasizes that the class action route can yield significant benefits for all parties involved, as they pursue recovery for losses incurred.

Conclusion

With October 13, 2026, fast approaching, it is imperative for affected investors in Aardvark Therapeutics to act without delay. The opportunity to seek justice and recovery from damages caused by misleading corporate disclosures is now. For further updates and additional information, please follow Faruqi & Faruqi on their social media channels or reach out directly as the legal landscape evolves.

This advisory by Faruqi & Faruqi is instrumental for Aardvark investors now more than ever, highlighting the firm's unwavering commitment to safeguarding investor rights.